Adalimumab/etanercept
1
Reactions 1478, p5 - 16 Nov 2013 ★ Adalimumab/etanercept Atopic dermatitis (first report with adalimumab) in an elderly patient: case report A 65-year-old woman developed atopic dermatitis (AD) following treatment with adalimumab and etanercept. The woman had rheumatoid arthritis. She was using SC adalimumab 40mg [frequency not stated]. She developed an intense pruritic eczema in her flexures after 2 months. Eosinophilia and IgE elevation were seen on her blood tests. Adalimumab was withdrawn, and the woman was treated with desonide. Her lesions disappeared. After 3 months, she started using etanercept [dosage and route not stated]. She developed new eczema lesions with eosinophilia [duration of etanercept treatment to reaction onset not stated]. Etanercept was withdrawn. Her pruritus and AD lesions improved, and total control was achieved in 2 weeks. Author comment: "AD is another rare side effect of the TNF-α inhibitors, such as adalimumab and etanercept." Pires MC, et al. Atopic dermatitis as a side effect of anti-TNFa. Dermatitis 24: 12, No. 4, Jul-Aug 2013. Available from: URL: http://dx.doi.org/10.1097/ DER.0b013e31829ccfc5 [abstract] - Brazil 803095710 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of atopic dermatitis associated with adalimumab. The WHO ADR database contained 10 reports of dermatitis atopic associated with adalimumab. 1 Reactions 16 Nov 2013 No. 1478 0114-9954/13/1478-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
-
Upload
jose-maria -
Category
Documents
-
view
219 -
download
4
Transcript of Adalimumab/etanercept
Reactions 1478, p5 - 16 Nov 2013
★Adalimumab/etanercept
Atopic dermatitis (first report with adalimumab) inan elderly patient: case report
A 65-year-old woman developed atopic dermatitis (AD)following treatment with adalimumab and etanercept.
The woman had rheumatoid arthritis. She was using SCadalimumab 40mg [frequency not stated]. She developed anintense pruritic eczema in her flexures after 2 months.Eosinophilia and IgE elevation were seen on her blood tests.
Adalimumab was withdrawn, and the woman was treatedwith desonide. Her lesions disappeared. After 3 months, shestarted using etanercept [dosage and route not stated]. Shedeveloped new eczema lesions with eosinophilia [duration ofetanercept treatment to reaction onset not stated]. Etanerceptwas withdrawn. Her pruritus and AD lesions improved, andtotal control was achieved in 2 weeks.
Author comment: "AD is another rare side effect of theTNF-α inhibitors, such as adalimumab and etanercept."Pires MC, et al. Atopic dermatitis as a side effect of anti-TNFa. Dermatitis 24: 12,No. 4, Jul-Aug 2013. Available from: URL: http://dx.doi.org/10.1097/DER.0b013e31829ccfc5 [abstract] - Brazil 803095710
» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports of atopicdermatitis associated with adalimumab. The WHO ADRdatabase contained 10 reports of dermatitis atopic associatedwith adalimumab.
1
Reactions 16 Nov 2013 No. 14780114-9954/13/1478-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
